Interactions with Rapporteurs (in spe) EMA 2011, May Bertil Jonsson - - PowerPoint PPT Presentation

interactions with rapporteurs in spe
SMART_READER_LITE
LIVE PREVIEW

Interactions with Rapporteurs (in spe) EMA 2011, May Bertil Jonsson - - PowerPoint PPT Presentation

Interactions with Rapporteurs (in spe) EMA 2011, May Bertil Jonsson Medical Products Agency Sweden 1 National ScA Whats in it for you? EMA/CHMP vs. MPA Complementary Format similar Q your position our view In the


slide-1
SLIDE 1

Interactions with Rapporteurs (in spe)

EMA 2011, May Bertil Jonsson Medical Products Agency Sweden

1

slide-2
SLIDE 2

What’s in it for “you”?

EMA/CHMP vs. MPA Complementary Format similar Q – your position – our view In the National Advice Dialogue always offered New issues may be raised Thinking outside the box? Better suited for early interactions?

2

National ScA

slide-3
SLIDE 3

National ScA

What’s in it for “me”?

  • Learning by doing
  • New as well as experienced assessors
  • Exchange of ideas
  • Finding new answers to old qustions

3

slide-4
SLIDE 4

Joint Advice MPA-TLV

  • Initially the idea came from industry
  • Objectives:

– provide parallel Scientific Advice – create a better understanding between assessors for methodologies used at MPA and TLV – create (an even) better interaction between the two agencies

  • Pilot that started September 2009 and was finalized by

end of 2010

4

slide-5
SLIDE 5

How was the pilot organised?

  • MPA and TLV assigned participants
  • MPA and TLV discussed the questions independently

prior to the meeting

  • A (short) joint discussion before the meeting
  • Meetings took place at the MPA
  • MPA and TLV answered respective questions – the

different roles of the agencies recognized (important to keep separate) although the process for providing advice is common.

  • Industry to provide feed-back after the meeting

5

slide-6
SLIDE 6

Joint Scientific Advice MPA-TLV

  • Twelve joint advices were performed in the pilot
  • Most of the requests came from big pharma but small

pharma was also represented

  • An evaluation of the pilot was performed by the end of

2010

6

slide-7
SLIDE 7

Has it worked?

  • Practical aspects? – absolutely (but it has required

some more of planning)

  • Met its objectives?

– provided advice to industry – yes – increased understanding of methodologies and the clinical trial setting needed to provide valuable information – yes – overall better collaboration between agencies – yes – Informative to industry – yes (?)

7

slide-8
SLIDE 8

8

The agencies have agreed to provide the possibility of joint advices on a regular basis since the beginning of 2011. Since we decided to offer joint advices on a more regular basis we have recieved very few requests, fewer than expected from the experience from the pilot. Why?

Current situation

slide-9
SLIDE 9

Presubmission Meetings

Objectives

  • Social

– It is about working together

  • Exchange Thoughts

– Strengths and deficiencies of the file – “No pre-assessment meeting”

  • Practical

– Issues to be specifically addressed in the overview – How to organise, e.g. The Summary of Safety

9

slide-10
SLIDE 10

Other points of interaction

  • During the procedure

– Clarification meetings (LoQ, draft answers) – Debriefing after SAG, CHMP meetings

  • Prior to large variations
  • New major safety signals

10

slide-11
SLIDE 11

It is a long-term relationship

Thank You